Post-treatment measurable residual disease (MRD) assessment via ctDNA offers a non-invasive, real-time response evaluation in large B-cell lymphoma (LBCL).
A commercially available immunoglobulin rearrangement-targeted ctDNA assay (clonoSEQM) enabled rapid MRD detection within a median of 9 days in a multicenter real-world cohort.
Detectable ctDNA MRD at end of frontline or CAR-T therapy strongly predicted inferior progression-free survival (PFS), underscoring its prognostic value.
The study supports integration of ctDNA MRD testing into routine clinical practice to guide personalized management strategies in LBCL.
